|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.45 USD | -2.34% |
|
-1.22% | +18.07% |
| 16/07 | Halozyme Therapeutics' strategic adoption |  |
| 11/07 | Halozyme Therapeutics Insider Sold Shares Worth $3,387,517, According to a Recent SEC Filing | MT |
| Capitalization | 695.58Cr 596.81Cr 556.06Cr 517.37Cr 954.55Cr 60TCr 1.07TCr 6.72TCr 2.54TCr 28TCr 2.61TCr 2.56TCr 1,03200Cr | P/E ratio 2025 * |
11.9x | P/E ratio 2026 * | 8.65x |
|---|---|---|---|---|---|
| Enterprise value | 735.99Cr 631.48Cr 588.37Cr 547.42Cr 1.01TCr 63TCr 1.13TCr 7.11TCr 2.68TCr 30TCr 2.76TCr 2.7TCr 1,09200Cr | EV / Sales 2025 * |
5.9x | EV / Sales 2026 * | 4.39x |
| Free-Float |
98.92% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Halozyme Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | -2.34% | ||
| 1 week | -1.22% | ||
| Current month | +8.52% | ||
| 1 month | +6.21% | ||
| 3 months | -3.98% | ||
| 6 months | +3.01% | ||
| Current year | +18.07% |
| 1 week | 56.38 |  | 58.56 |
| 1 month | 51.06 | | 58.56 |
| Current year | 47.5 | | 70.5 |
| 1 year | 42.01 | | 70.5 |
| 3 years | 29.85 | | 70.5 |
| 5 years | 25.17 | | 70.5 |
| 10 years | 6.96 | | 70.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Helen Torley
CEO | Chief Executive Officer | 62 | 06/01/2014 |
Nicole LaBrosse
DFI | Director of Finance/CFO | 42 | 02/02/2022 |
Charles Theuer
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Matthew Posard
BRD | Director/Board Member | 58 | 28/03/2013 |
Helen Torley
BRD | Director/Board Member | 62 | 06/01/2014 |
| Chairman | 60 | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.34% | -1.22% | +4.46% | +12.76% | 695.58Cr | ||
| -0.85% | -1.95% | -27.50% | -33.11% | 5.6TCr | ||
| -0.51% | +1.73% | -20.28% | -21.52% | 889.64Cr | ||
| -2.80% | +18.17% | +35.66% | +152.22% | 710.47Cr | ||
| -0.10% | +4.78% | +19.35% | +32.56% | 580.84Cr | ||
| +3.01% | +9.08% | +98.24% | +17.48% | 368.96Cr | ||
| +2.71% | +6.36% | +106.73% | +44.61% | 204.2Cr | ||
| -1.89% | -0.82% | -11.07% | +16.15% | 204.18Cr | ||
| -3.72% | -2.36% | +6.91% | +7.98% | 202.51Cr | ||
| +1.87% | +4.90% | +47.99% | -21.65% | 200.96Cr | ||
| Average | -0.46% | +4.03% | +26.05% | +20.75% | 966.18Cr | |
| Weighted average by Cap. | -0.83% | +1.23% | -6.80% | -5.45% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 124.83Cr 107.1Cr 100Cr 93Cr 171.31Cr 11TCr 191.28Cr 1.21TCr 455.09Cr 5.04TCr 468.24Cr 458.54Cr 19TCr | 149.98Cr 128.68Cr 119.9Cr 111.55Cr 205.82Cr 13TCr 229.81Cr 1.45TCr 546.77Cr 6.06TCr 562.57Cr 550.91Cr 22TCr |
| Net income | 60Cr 51Cr 48Cr 44Cr 82Cr 5.14TCr 91Cr 576.32Cr 217.56Cr 2.41TCr 223.84Cr 219.2Cr 8.86TCr | 81Cr 70Cr 65Cr 60Cr 111.28Cr 6.98TCr 124.26Cr 783.17Cr 295.64Cr 3.27TCr 304.18Cr 297.88Cr 12TCr |
| Net Debt | 40Cr 35Cr 32Cr 30Cr 55Cr 3.48TCr 62Cr 390.26Cr 147.32Cr 1.63TCr 151.58Cr 148.44Cr 6TCr | -37Cr -31Cr -29Cr -27Cr -50Cr -3.16TCr -56Cr -354.06Cr -133.65Cr -1.48TCr -137.51Cr -134.67Cr -5.44TCr |
More financial data
* Estimated data
Employees
350
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/25/18 | 56.45 $ | -2.34% | 11,11,563 |
| 17/25/17 | 57.80 $ | -0.35% | 11,10,491 |
| 16/25/16 | 58.01 $ | +2.49% | 14,34,304 |
| 15/25/15 | 56.60 $ | -1.82% | 10,01,416 |
| 14/25/14 | 57.65 $ | +0.87% | 10,99,408 |
Delayed Quote Nasdaq, July 19, 2025 at 01:30 am IST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
56.45USD
Average target price
65.89USD
Spread / Average Target
+16.72%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HALO Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition